Crowley Wealth Management Inc. Buys New Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Crowley Wealth Management Inc. bought a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) during the fourth quarter, HoldingsChannel reports. The firm bought 3,927 shares of the company’s stock, valued at approximately $52,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Versant Capital Management Inc acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at about $26,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Takeda Pharmaceutical in the third quarter valued at about $40,000. BNP Paribas Financial Markets increased its position in shares of Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after acquiring an additional 2,596 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after acquiring an additional 1,976 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in shares of Takeda Pharmaceutical in the third quarter valued at about $52,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $15.20 on Monday. The business’s 50 day moving average price is $13.96 and its two-hundred day moving average price is $13.91. The company has a market cap of $48.35 billion, a PE ratio of 37.99, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.31.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.